The two pivotal Phase III studies of ACZ885 (canakinumab), a medication that has the potential to treat gouty arthritis, have yielded positive results, according to Novartis. About 450 people with gouty arthritis participated in the two Phase III, 12-week, randomised, multicentre, double-blind, double-dummy, and active-controlled studies, which demonstrated that the drug provided pain relief...